Literature DB >> 9733972

Striking changes in anxiety in Huntington's disease transgenic mice.

S E File1, A Mahal, L Mangiarini, G P Bates.   

Abstract

Huntington's disease transgenic mice were tested in the elevated plus-maze test of anxiety at 6, 8, 10 and 12 weeks of age. At all ages, they showed significant and striking increases in the percentages of open arm entries and time spent on the open arms, compared with their normal littermates, indicating reduced anxiety. These increases were not secondary to a non-specific stimulant effect, since the transgenic mice made fewer closed arm entries, significantly so from 10 weeks of age. The mice were also tested in the holeboard, which provides measures of locomotor activity and directed exploration. From 8 weeks of age, the Huntington's mice were significantly less active than their normal littermates and made fewer exploratory head-dips. The increased open arm activity in the elevated plus-maze cannot therefore be secondary to increased exploration in the transgenic mice. In order to determine whether the reduced anxiety was due to differences in benzodiazepine receptor function, the mice were challenged with the benzodiazepine receptor antagonist, flumazenil. The results indicated that some of the reduced anxiety could be attributed to the presence of an endogenous anxiolytic ligand. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733972     DOI: 10.1016/s0006-8993(98)00736-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.

Authors:  Mark F Mehler; Jenna R Petronglo; Eduardo E Arteaga-Bracho; Maria E Gulinello; Michael L Winchester; Nandini Pichamoorthy; Stephen K Young; Christopher D DeJesus; Hifza Ishtiaq; Solen Gokhan; Aldrin E Molero
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

3.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

Review 4.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

5.  Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation.

Authors:  L A Lione; R J Carter; M J Hunt; G P Bates; A J Morton; S B Dunnett
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

6.  Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.

Authors:  Chi-Tso Chiu; Guangping Liu; Peter Leeds; De-Maw Chuang
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

7.  Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Authors:  Liliana B Menalled; Jessica D Sison; Ying Wu; Melisa Olivieri; Xiao-Jiang Li; He Li; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  Towards humane end points: behavioural changes precede clinical signs of disease in a Huntington's disease model.

Authors:  Kate Littin; Abraham Acevedo; William Browne; Joanne Edgar; Mike Mendl; Diane Owen; Chris Sherwin; Hanno Würbel; Christine Nicol
Journal:  Proc Biol Sci       Date:  2008-08-22       Impact factor: 5.349

Review 9.  Lessons learned from the transgenic Huntington's disease rats.

Authors:  Rinske Vlamings; Dagmar H Zeef; Marcus L F Janssen; Mayke Oosterloo; Frederic Schaper; Ali Jahanshahi; Yasin Temel
Journal:  Neural Plast       Date:  2012-07-18       Impact factor: 3.599

Review 10.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.